Skeletal sexual dimorphism: relative contribution of sex steroids, GH–IGF1, and mechanical loading

Filip Callewaert, Mieke Sinnesael, Evelien Gielen, Steven Boonen and Dirk Vanderschueren
Center for Musculoskeletal Research, Department of Experimental Medicine, Katholieke Universiteit Leuven, Herestraat 49, B-3000 Leuven, Belgium
(Correspondence should be addressed to D Vanderschueren; Email: dirk.vandderschueren@uz.kuleuven.be)

Abstract

Structural gender differences in bone mass – characterized by wider but not thicker bones – are generally attributed to opposing sex steroid actions in men and women. Recent findings have redefined the traditional concept of sex hormones as the main regulators of skeletal sexual dimorphism. GH–IGF1 action is likely to be the most important determinant of sex differences in bone mass. Estrogens limit periosteal bone expansion but stimulate endosteal bone apposition in females, whereas androgens stimulate radial bone expansion in males. Androgens not only act directly on bone through the androgen receptor (AR) but also activate estrogen receptor-α or -β (ERα or ERβ) following aromatization into estrogens. Both the AR and ERα pathways are needed to optimize radial cortical bone expansion, whereas AR signaling alone is the dominant pathway for normal male trabecular bone development. Estrogen/ERα-mediated effects in males may – at least partly – depend on interaction with IGF1. In addition, sex hormones and their receptors have an impact on the mechanical sensitivity of the growing skeleton. AR and ERβ signaling may limit the osteogenic response to loading in males and females respectively, while ERα may stimulate the response of bone to mechanical stimulation in the female skeleton. Overall, current evidence suggests that skeletal sexual dimorphism is not just the end result of differences in sex steroid secretion between the sexes, but depends on gender differences in GH–IGF1 and mechanical sensitivity to loading as well.

Introduction

Sex steroids are mainly synthesized by the gonads (testis and ovary), but the adrenals constitute an additional source (Vanderschueren et al. 2004, Callewaert et al. 2010a). Sex steroids are involved in the regulation of a number of important physiological processes, including sexual differentiation of the genitalia, sexual maturation, and reproduction. Sex hormones also have an impact on skeletal homeostasis, because they add bone during puberty and subsequently maintain skeletal integrity, both in men and women (Riggs et al. 2002). However, gender differences in bone growth become apparent during puberty, with men reaching higher peak bone mass, greater bone size, and, ultimately, a stronger skeleton compared to women (Garn 1970, Seeman 2001). Puberty builds a bigger, but not a denser, skeleton in males, as bone mineral acquisition in long bones occurs in proportion to the volume of the bone (Zamberlan et al. 1996). As a result, the volumetric bone mineral density (BMD) does not differ between men and women. In addition, growth during puberty also builds wider and slightly taller vertebral bodies in men, without sex differences in trabecular BMD (Gilsanz et al. 1994). As a result of these stronger structural features achieved during growth, the male skeleton is less susceptible to osteoporosis later in life (Seeman 2002). Although fewer men than women sustain fractures during aging, fragility fractures are common in men and are associated with a significant burden in terms of morbidity, mortality, and economic cost to the community (Boonen et al. 2007, Khosla et al. 2008).

Therefore, more insight into the mechanisms involved in bone mass acquisition is essential to improve our understanding of the pathophysiology of osteoporosis and osteoporotic fracture risk in men.

Skeletal gender differences in radial bone growth (skeletal sexual dimorphism) are traditionally attributed to stimulatory ‘male’ androgen action as opposed to inhibitory ‘female’ estrogen action on periosteal bone formation. However, particularly in men, the mechanism of action of sex steroids on bone growth appears considerably more complex. Testosterone, the main circulating androgen in males, not only activates the androgen receptor (AR) but also acts on the estrogen receptor-α or -β (ERα or ERβ) following...
aromatization into 17β-estradiol (E₂; Vanderschueren et al. 2004, Callewaert et al. 2010a). Experiments in animals as well as in a number of case reports of men with either a loss-of-function mutation in ERα or an aromatase deficiency provided evidence that estrogens play a key role in male skeletal homeostasis (Smith et al. 1994, 2008, Vanderschueren et al. 1997, Vidal et al. 2000, Bouillon et al. 2004, Rochira et al. 2007). In addition to sex steroids, other hormones such as GH and insulin-like growth factor 1 (IGF1) may further contribute to the development of the skeletal sexual dimorphism. GH and IGF1 – the GH–IGF1 axis – are both primarily responsible for postnatal growth (Lupu et al. 2001). Moreover, sex steroids and the GH–IGF1 axis interact closely during puberty (Mauras et al. 1996), optimizing bone mass acquisition during pubertal growth. Finally, skeletal growth is further stimulated by mechanical loading (Frost 2003), which in turn may be influenced by sex hormones as well. In fact, mechanical loading increases bone formation in close association with estrogen signaling, at least in female mice (Lee et al. 2003). Thus, sex steroids, IGF1, and mechanical stimuli may both independently and mutually affect the acquisition of an optimal bone mass during puberty. In this review, three major questions will be addressed: 1) to what extent do sex steroids or GH–IGF1 or both influence the skeletal gender differences; 2) what is the relative importance of AR and ERα signaling in the acquisition of male cortical and trabecular bone mass; and 3) do sex steroids and their receptors affect the adaptive response of bone to loading?

Hormonal factors involved in the development of the skeletal sexual dimorphism

Evidence for a role of androgens and estrogens

Puberty represents a critical growth period during which important gender differences in bone width and strength are established. In fact, boys develop a larger periosteal perimeter than girls from mid-puberty onward (Seeman 2001, Kirmani et al. 2009). In contrast, girls experience less periosteal expansion but more endocortical apposition compared to boys. As a result, men not only build up wider bones but also stronger bones, with cortical bone further away from the neutral axis of the long bone and more resistant to bending. Sex hormones have traditionally been considered the primary mediator of skeletal sexual dimorphism in bone size and strength. This prevailing opinion was established by the observation of a reduced periosteal perimeter in orchidectomized growing male rats versus an increased periosteal circumference in ovariectomized female rats (Turner et al. 1990). This landmark study led to the assumption that androgens were stimulatory and estrogens inhibitory for male and female radial bone growth respectively. In line with this concept, a study in pubertal mouse models showed that androgen withdrawal, as induced by orchidectomy, decreases radial bone expansion in males (Callewaert et al. 2010b). Ovariectomy, on the other hand, increases radial bone growth in females (Callewaert et al. 2010b). However, these hormonal effects differ in their timing of action, as the androgen-mediated effects occur only during later stages of puberty, compared with the earlier effect of estrogens and are in line with the traditional concept that androgens stimulate male bone size whereas estrogens limit female bone size. However, recent findings have partly redefined this concept, with a significant body of evidence pointing to a role of estrogen action in males as well. In male mice, estrogen deficiency on top of androgen withdrawal further reduces radial bone expansion, at least during the early stages of puberty (Callewaert et al. 2010b), in line with the concept that aromatization of androgens into estrogens also contributes to the skeletal gender differences (Fig. 1).

Evidence for a critical role of GH–IGF1

Other hormones such as GH and IGF1 also manifestly increase during puberty and are regarded as critical regulators of pubertal bone growth as well (Mauras et al. 1996). Importantly, GH–IGF1 action even appears to be the most important determinant of gender differences in bone mass in pubertal mice (Callewaert et al. 2010b). IGF1 levels are indeed higher in male versus female mice during early puberty, the time window during which most of the gender differences are established. Moreover, mice with a disrupted GH receptor (GHR) – associated with extremely low IGF1 levels – also have a severely reduced radial bone expansion without gender differences in radial bone growth (Callewaert et al. 2010b). Earlier observations of severe growth retardation in mice lacking GHR, IGF1, or both support the crucial role of GH and IGF1 in the control of postnatal bone growth (Lupu et al. 2001; Fig. 1). Human and animal studies agree with this concept, as IGF1 treatment in GHR knockout (KO) mice or patients with GH resistance stimulates growth or even reverses the detrimental effects of GHR deficiency (Laron 1999, Sims et al. 2000). Beside this direct action of GH/IGF1, however, there is also ample evidence for an interacting role of sex steroids and IGF1. For instance, the pubertal increase in GH–IGF1 appears to be mediated by the sex steroids. Neonal testosterone secretion establishes the GH secretion pattern, which, in turn, also determines masculinization of hepatic steroid metabolism (Jansson et al. 1985). In addition, perinatal androgens appear to be a key determinant of adult bone length in males, as shown by the lower femoral and tibial length in androgen-deficient hypogonadal mice compared with age-matched orchidectomized mice (Sims et al. 2006). In addition, it is now well established, both in humans and animals, that estrogens may interact with the GH–IGF1 axis (Juul 2001, Venken et al. 2005). In fact, estrogen-related changes in male bone mass seem to be IGF1-dependent. In male mice, estrogen-dependent skeletal changes are associated with lower IGF1 levels during early puberty. Similar findings have been reported in ERαKO mice and male rats treated with an aromatase inhibitor (Vanderschueren et al. 1997, Vidal et al. 2000). Likewise, aromatase inhibition in
adolescent boys decreases estrogen levels and is associated with a concomitant reduction in IGF1 levels (Mauras et al. 2000). Moreover, a recent study in cartilage-specific ERα KO mice showed that low E2 levels during early skeletal maturation stimulate longitudinal bone growth through actions on the GH–IGF1 axis, independent of ERα in growth plate cartilage (Borjesson et al. 2010). Collectively, a significant body of evidence identifies GH/IGF1 as a critical regulator of skeletal gender differences. Nevertheless, the notion that sex steroids may interact with IGF1 suggests that the androgens and estrogens may indirectly affect the skeletal sexual dimorphism as well, through interaction with GH–IGF1 (Fig. 1).

Overall, the development of skeletal sexual dimorphism in mice resembles the human situation, since most of the gender differences in bone mass are established during puberty and associated with similar hormonal changes (Fig. 1). Nevertheless, some differences become apparent as well. In humans, it is generally accepted that sex differences in bone morphology are the result of the earlier onset of puberty in girls and the longer duration of puberty in boys, without major differences in absolute growth rate between sexes (Seeman 2002, Iuliano-Burns et al. 2009). In mice, on the other hand, absolute gender differences in periosteal and endocortical bone formation also contribute to the development of the skeletal sexual dimorphism (Callewaert et al. 2010b). In fact, periosteal and endosteal bone formation rates, as determined by dynamic histomorphometry, are higher and lower respectively in male versus female mice. Obviously, similar information on dynamic bone formation rates in humans is not available. Differences with respect to pubertal GH–IGF1 secretion may exist between humans and mice as well. In contrast to mice, peak IGF1 levels are not different between boys and girls. However, girls have an earlier IGF1 peak associated with the earlier onset of puberty (Leger et al. 2007). Overall, extrapolation of mice data on hormonal determinants of skeletal sexual dimorphism to the human condition should be handled with caution.

### Relative importance of androgens and estrogens during male bone growth

It has become increasingly clear that androgen signaling in males is far more complex than originally anticipated. A significant body of evidence in humans and animals has firmly established that at least part of the androgen-mediated bone growth in males may be mediated through conversion of androgens into estrogens and subsequent ERα activation. In fact, aromatase-deficient men, estrogen-resistant men, as well as transgenic mice lacking the aromatase or ERα gene all present with low bone mass (Vidal et al. 2000, Miyaura et al. 2001, Bouillon et al. 2004, Rochira et al. 2007, 2009).
Together, these findings support the view that estrogens are indispensable for male skeletal health. Nevertheless, more conclusive evidence on the relative importance and differential roles of AR and ERα in cortical and trabecular bone mass accrual and maintenance was only recently provided by the longitudinal evaluation of male mice lacking both AR and ERα (Callewaert et al. 2009). This study supports AR activation as being solely responsible for the development and maintenance of male trabecular bone mass, since AR inactivation – in the presence or absence of ERα – results in a severely reduced trabecular bone mass with increased bone turnover (Callewaert et al. 2009). Similar changes (also described in other ARKO models; Kawano et al. 2003, Venken et al. 2006) are the main features of hypogonadal osteoporosis as well (Finkelstein et al. 1989). Along the same line, testosterone treatment restores orchidectomy-induced trabecular bone loss in male mice (Venken et al. 2006), adding further evidence to the concept of AR signaling as a critical regulator of the development of normal male trabecular bone mass. On the other hand, administration of an aromatase inhibitor in ARKO and orchidectomized mice has no effect on trabecular bone (Venken et al. 2006), suggesting that residual ERα activation fails to restore or compensate AR-mediated bone loss. This lack of a role of ERα during male trabecular bone growth sharply contrasts to the important role of ERα in female mice (Lindberg et al. 2001), or with the pharmacological effect of (supraphysiological) estrogen administration in orchidectomized male mice (Vandenput et al. 2001). Moreover, various studies even report an increased trabecular bone mass in ERαKO mice (Vandenput et al. 2001, Sims et al. 2003, Callewaert et al. 2009), which could be attributed to higher androgen levels acting through the AR. In line with this assumption, surgical castration or anti-androgen treatment of ERαKO mice normalizes the trabecular bone mass in these mice (Vandenput et al. 2001, Sims et al. 2003). Together, these observations clearly define AR and ERα activation as the primary determinant of trabecular bone development in male and female mice respectively.

In contrast to their role in trabecular bone, AR and ERα are both required for optimal stimulation of male cortical bone mass in male mice. In fact, AR–ERα ‘double’ KO mice have lower cortical bone mass compared with either ARKO or ERαKO mice alone (Callewaert et al. 2009). Likewise, administration of an aromatase inhibitor further reduces cortical bone mass in orchidectomized mice (Callewaert et al. 2010b). In line with these findings, testosterone action on periosteal bone formation and cortical thickness is blunted by an aromatase inhibitor in orchidectomized mice (Venken et al. 2006). The importance of aromatization of androgens into estrogens for cortical bone expansion is also supported by observations in humans. Cortical bone dimensions failed to enlarge in an adolescent aromatase–deficient boy despite supranormal testosterone concentrations (Bouillon et al. 2004). In this patient, estrogen treatment substantially increased bone size, suggesting that optimal cortical bone expansion requires activation of both AR and ERα, not only in mice but also in humans. Beside ERα, estrogens might also activate ERβ. In contrast to female ERβKO mice – which showed an increased cortical bone mineral content and cross-sectional area – ERβ does not appear to play any role in male skeletal growth, since male ERβKO do not display a bone phenotype (Windahl et al. 1999, Vidal et al. 2000, Sims et al. 2002). Thus, ERα but not ERβ appears to mediate estrogen actions during male skeletal growth. Although AR activation is the dominant pathway of androgen signaling for male trabecular bone growth and maintenance, it would seem therefore that AR and ERα activation are both required to optimize cortical bone growth (Fig. 2).

Androgen signaling and the mechanical sensitivity of the male skeleton

Functional response of bone to loading

Mechanical loading has a major impact on skeletal growth. The change in the body weight and the resulting mechanical stimulation of the skeleton during puberty are substantial. Since overall growth rate is higher in males than females, the male skeleton encounters higher mechanical demands. It is therefore tempting to speculate that this higher load bearing in males also stimulates bone growth to a greater extent than in females, as reflected by more periosteal bone formation during puberty (Callewaert et al. 2010b). The stimulatory role of mechanical loading and physical activity on bone expansion has been well documented in numerous experimental and clinical studies. A range of noninvasive axial loading models, using various animal models subjected to different exercise regimens, have provided insights into the anabolic response of bone to loading (Mosley et al. 1997, Mosley & Lanyon 1998, Hsieh & Turner 2001, Srinivasan et al. 2002). Overall, these animal studies have consistently indicated that mechanical loading influences the morphology of growing bone by increasing bone formation more than resorption. In humans, most evidence is derived from cross-sectional observations. For instance, tennis players have been shown to have larger cortical thickness in the dominant playing arm compared with the nonplaying arm (Bass et al. 2002). Moreover, the increase in bone mass in elite gymnasts persists after retirement, suggesting that the beneficial effects of loading may induce lifelong benefits to bone strength (Bass et al. 1998). Similar findings have been obtained in a few longitudinal studies, reporting significant side-to-side differences in bone size and strength in tennis players 1.5–3 years after retirement (Haapasalo et al. 2000). However, the assumption that skeletal benefits obtained from exercise may be maintained into older age remains uncertain, as unequivocal longitudinal evidence is currently lacking. The timing and duration of exercise also influences the response to loading in humans. In fact, different responses to loading have been reported in pre-, peri-, and postpubertal tennis players.
In female players, loading before puberty and during early puberty enhances periosteal bone formation and bone strength, whereas loading during late puberty bone is mainly accumulated at the endocortical bone surface without major changes in bone strength (Bass et al. 2002). In male players, on the other hand, periosteal expansion in response to loading is most pronounced in prepubertal and peripubertal boys and then tends to plateau (Ducher et al. 2009). It would seem therefore that pubertal growth and sex hormones appear to influence the adaptive response to exercise, and this interaction may be different in boys and girls.

**Interaction of sex steroids and mechanical loading**

Sex steroids may also modulate the response of bone to mechanical stimulation. This hypothesis originates from rodent studies, showing that female rats have more bone than male rats relative to body weight (Saville 1969, Wang et al. 2003). A study in human observed a similar evolution, as the increase in bone mass relative to muscle mass is greater in girls compared with boys during puberty (Schiessl et al. 1998), even after adjustment for fat mass (Ferretti et al. 1998). These observations suggest that estrogens alter the mechanosensitivity of bones, so that more bone is accumulated than is needed mechanically. Moreover, it has been hypothesized that estrogen withdrawal during menopause impairs the mechanically adaptive mechanism, and hereby contributes to postmenopausal bone loss and the development of osteoporosis (Lanyon & Skerry 2001). Exercise, however, is generally believed to stimulate periosteal bone formation, whereas estrogen appears to have an inhibitory effect in females – at least in mice (Callewaert et al. 2010b). For instance, prepubertal female tennis players with low estrogen concentrations show a more favorable periosteal response compared to postpubertal girls with high estrogen levels (Bass et al. 2002). Concurrently, estrogen supplementation in male rats appears to suppress the periosteal response to mechanical loading (Saxon & Turner 2006). According to in vitro as well as in vivo rodent studies, sex steroid signaling and mechanical loading may also share common signaling pathways. Estrogen and mechanical strain stimulate proliferation independently in osteoblast-like cells derived from male and female rats as well as in human osteoblast cells (Damien et al. 2000, Cheng et al. 2002). Nevertheless, ER modulators and antagonists block the increase in proliferation in response to mechanical strain, whereas dihydrotestosterone (DHT) and AR activation apparently are not involved. These findings suggest that ERs, but not AR, influence the response to strain. As a proof of this concept, periosteal bone formation in response to in vivo ulna loading is significantly reduced in female ERKO mice (Lee et al. 2003). In contrast, disruption of ERβ increases periosteal bone formation following loading in female but not in male mice (Saxon et al. 2007). Together, these findings clearly indicate that sex hormone signaling interferes with the mechanical response to loading, at least in female mice, with ERα and ERβ having antagonistic effects. A recent report also investigated the role of sex steroid receptors in the mechanical sensitivity of the male skeleton (Callewaert et al. 2010c). This study suggests that ERα does not interfere with the adaptive response in males, which is in sharp contrast with the above-mentioned crucial role of ERα in females. Indeed, periosteal bone formation is similarly increased following loading in male ERαKO compared with wild-type mice. The apparent gender-dependent importance of ERα in mice is also supported by observations in humans, since puberty and sex steroid exposure influence the mechanical bone response.
different in boys and girls (Bass et al. 2002, Ducher et al. 2009). In addition, AR activation may even limit the response to mechanical stimulation, since AR deletion – both in the presence and absence of ERα – increases the periosteal bone response to loading (Callewaert et al. 2010a). AR signaling not only increases periosteal bone formation following loading, but also lowers SOST and sclerostin expression (Callewaert et al. 2010a). Sclerostin, which is encoded by the SOST gene, is the principal osteocyte-specific inhibitor of bone formation known to antagonize Wnt/β-catenin signaling (Poole et al. 2005, ten Dijke et al. 2008). The role of osteocyte-specific sclerostin signaling in mechanotransduction has previously been demonstrated in both loading and unloading conditions (Robling et al. 2008, Lin et al. 2009). Therefore, AR signaling may interfere with the inhibiting effect of sclerostin signaling on bone formation. In conclusion, in vitro and in vivo animal data as well as observations in humans have indicated that estrogen may modulate the effects of loading in females. In fact, ERα activation is required for the full osteogenic response to loading, whereas ERβ activation appears to inhibit periosteal bone formation following loading in females. In contrast to female mice, ERα and ERβ apparently are not involved in the response to loading in male mice. AR signaling, on the other hand, limits the anabolic response to mechanical loading in male mice, possibly through interaction with sclerostin signaling (Fig. 3).

Conclusion

GH/IGF1 action, more than sex steroid action, appears to be the primary determinant of gender differences in pubertal bone growth, which, in turn, may be influenced by sex hormones (e.g. neonatal imprinting). Beside GH/IGF1, estrogens limit periosteal bone expansion but stimulate endocortical apposition in females. In males, both androgens and estrogens stimulate periosteal bone expansion and hence cortical bone growth during puberty. However, estrogen action on male cortical bone may at least partly be explained by concomitant changes in IGF1 (Fig. 1). In contrast with its role in cortical bone growth, AR activation alone is sufficient for the development of trabecular bone mass in males (Fig. 2). Finally, sex steroids and their receptors also have an impact on the mechanical sensitivity of the male and female skeleton. AR and ERβ signaling limit the osteogenic response to mechanical loading in male and female mice respectively. ERα activation, on the other hand, stimulates bone formation in response to mechanical loading in female but not male mice (Fig. 3). Therefore, skeletal sexual dimorphism is not only determined by androgen action in males and estrogen action in females respectively but also by complex gender- and time-specific interactions between sex hormones, GH–IGF1, and mechanical loading.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This review was supported by grants OT/05/53 and OT/09/035 from the Catholic University Leuven (K U Leuven) and grant G.0605.07 from the Fund for Scientific Research Flanders, Belgium (F W O-Vlaanderen).

Acknowledgements

S Boonen is a senior clinical investigator of the Fund for Scientific Research (FWO-Vlaanderen) and holder of the Leuven University Chair in Gerontology and Geriatrics. D Vanderschueren is a senior clinical investigator of the Leuven University Hospital Clinical Research Fund.

References


Skeletal sexual dimorphism in mice


Received in final form 11 August 2010
Accepted 31 August 2010
Made available online as an Accepted Preprint 31 August 2010